Association between various cathepsins and uterine leiomyoma: A Mendelian randomization analysis.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2024
Historique:
received: 22 03 2024
accepted: 26 08 2024
medline: 12 9 2024
pubmed: 12 9 2024
entrez: 12 9 2024
Statut: epublish

Résumé

Emerging evidence suggests a tentative association between cathepsins and uterine leiomyoma (UL). Previous investigations have predominantly focused on the role of cathepsins in the metastasis and colonization of gynecological malignancies. Still, observational studies may lead to confounding and biases. We employed a bidirectional Mendelian randomization (MR) analysis to elucidate the causative links between various cathepsins and UL. Instrumental variables (IVs) of cathepsins and UL within the European cohort were from extant genome-wide association study datasets. Sensitivity assessments was executed, and the heterogeneity of the findings was meticulously dissected to affirm the solidity of the outcomes. Our findings reveal the association between cathepsin B (CTSB) and an elevated risk of developing UL (all cancers excluded) [Inverse Variance Weighted (IVW) method]: OR = 1.06, 95%CI [1.02, 1.11], P = 0.008895711. Although the association does not persist after multiple testing or Steiger filtering, this finding adds to our understanding of the causal relationship between CTSB of various cathepsins and UL (all cancers excluded) and may herald new therapeutic avenues for individuals affected by this condition.

Identifiants

pubmed: 39264885
doi: 10.1371/journal.pone.0310292
pii: PONE-D-24-11417
doi:

Substances chimiques

Cathepsin B EC 3.4.22.1
Cathepsins EC 3.4.-
CTSB protein, human EC 3.4.22.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0310292

Informations de copyright

Copyright: © 2024 Liu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Auteurs

Tingxiu Liu (T)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.

Yuehan Ren (Y)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.

Junning Zhang (J)

Beijing University of Chinese Medicine, Beijing, China.
Department of Oncology of Integrative Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.

Hechun Yin (H)

Qi-Huang Chinese Medicine School, Beijing University of Chinese Medicine, Beijing, China.

Zheng Zheng (Z)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Mingyue Zhang (M)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Yan Liao (Y)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.

Liangliang Yang (L)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.

Chang Liu (C)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Beijing University of Chinese Medicine, Beijing, China.

Xinmin Liu (X)

Department of Gynecology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Peiyu Yan (P)

Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, Macao, SAR, China.
State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology Zhuhai MUST Science and Technology Research Institute, Macao, Macao, SAR, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH